News Focus Channel: Cancer Center Featured Story 2

Patients with Heart Disease May Be at Increased Risk for Advanced Breast Cancer

University of Texas MD Anderson Cancer Center — Thu, 02 Jan 2025 11:00:00 EST

Patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis cardiovascular disease (CVD) compared to those with early-stage cancer at diagnosis, according to researchers from The University of Texas MD Anderson Cancer Center.

Buffalo Spree Names Record 143 Roswell Park Physicians as Top Doctors for 2025

Roswell Park Comprehensive Cancer Center — Mon, 30 Dec 2024 16:20:08 EST

As the year comes to a close, Roswell Park Comprehensive Cancer Center honors the 143 physicians across 35 specialties named to Buffalo Spree magazine's Top Doctors list for 2025. The annual list is compiled through surveys submitted by Western New York physicians.

UC Davis Researchers Help Decode the Cause of Aggressive Breast Cancer in Women of Color

UC Davis Health — Fri, 20 Dec 2024 17:55:13 EST

Cancer center researchers may have uncovered the specific biomarker that causes Black women to get triple-negative breast cancer at higher rates than other women.

The Secret Life of ALAS1: How a Basic Science Discovery Could Pave the Way for Better siRNA Therapies

Memorial Sloan Kettering Cancer Center — Fri, 20 Dec 2024 17:30:12 EST

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.

First Dual Chamber Leadless Pacemaker Implanted in a Child

UC Davis Health — Fri, 20 Dec 2024 14:55:49 EST

UC Davis pediatric cardiologist Dan Cortez is first in the world to implant a dual chamber leadless pacemaker in a child.

MD Anderson Research Highlights for December 18, 2024

University of Texas MD Anderson Cancer Center — Wed, 18 Dec 2024 22:15:07 EST

The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Roswell Park Team Discovers New Treatment Target for Neuroendocrine Prostate Cancer

Roswell Park Comprehensive Cancer Center — Wed, 18 Dec 2024 20:05:13 EST

A team of researchers at Roswell Park , led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer. Their findings, newly published in the journal Oncogene, suggest that a set of processes known as the mitochondrial unfolded protein response, could be an Achilles' heel for this often-deadly cancer type, and may point the way to a new treatment approach.

MSK Research Highlights, December 18, 2024

Memorial Sloan Kettering Cancer Center — Wed, 18 Dec 2024 19:00:00 EST

New research from Memorial Sloan Kettering Cancer Center (MSK) uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT(r) could be used for HLA genotype screening to predict response to cellular therapies; identifies a possible strategy to overcome immune evasion in ovarian cancer; and finds strong support for telemedicine visits among cancer patients.

Top Cancer Research Advances at MSK in 2024

Memorial Sloan Kettering Cancer Center — Tue, 17 Dec 2024 12:00:16 EST

Researchers at Memorial Sloan Kettering Cancer Center (MSK) continued to make strides against cancer in 2024. Laboratory research teams across the institution worked to advance the global understanding of cancer and to develop new therapies, while also making fundamental insights into human biology and disease.

Governor Hochul Celebrates the Opening Of New York's First Cell and Gene Therapy Hub at Roswell Park Comprehensive Cancer Center in Buffalo

Roswell Park Comprehensive Cancer Center — Mon, 16 Dec 2024 21:10:27 EST

Governor Kathy Hochul today celebrated the opening of the Roswell Park GMP Engineering and Cell Manufacturing Facility, New York's first cell and gene therapy hub, located at Roswell Park Comprehensive Cancer Center in Buffalo. The $98 million facility will create new jobs, help to support the research and development of life-saving cell and gene therapies at Roswell, significantly grow its well-established research capabilities, and establish Roswell as one of the premier cell therapy discovery and development institutions in the nation. The expansion also realizes Governor Hochul's 2023 State of the State commitment to bolster the state's leadership in the fast-growing CGT sector through establishment of an Upstate cell and gene therapy hub to catalyze its growth in western NY. The GEM facility meets U.S. FDA Good Manufacturing Practice standards for manufacture of clinical cell therapy products, positioning the Roswell Park team to be a multifaceted resource for patients, care teams

Memorial Sloan Kettering Physician-Scientists Develop Innovative Multimodal Machine Learning Model That Improves Prediction of Metastatic Breast Cancer Treatment Options

Memorial Sloan Kettering Cancer Center — Fri, 13 Dec 2024 18:10:23 EST

New research presented during the 2024 San Antonio Breast Cancer Symposium (SABCS) reveals a new machine learning model that could change the way metastatic breast cancer is treated in the future. By combining clinical and genomic data, physician-scientists from Memorial Sloan Kettering Cancer Center (MSK) developed a tool that could help improve predictions of how people with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer respond to CDK4/6 inhibitors, a class of oral medications that control cell division and are often prescribed in combination with hormone therapy to treat this subset of patients.

Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian Cancer

Roswell Park Comprehensive Cancer Center — Thu, 12 Dec 2024 20:35:58 EST

A study led by Roswell Park provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer. Newly published in Nature Communications, the findings emphasize the role of the patient's microbiome -- the collection of microorganisms in the body --and lay the groundwork for future clinical trials aimed at improving treatment outcomes.

MD Anderson's Lauren Averett Byers Receives TAMEST O'Donnell Award for Seminal Contributions to Lung Cancer Research

University of Texas MD Anderson Cancer Center — Wed, 11 Dec 2024 08:00:00 EST

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST). The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer (SCLC), which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.

HPV Genotype-Specific Prevalence and Infection Risks: A 10-Year Population-Based Study From the United States

University of New Mexico Comprehensive Cancer Center — Tue, 10 Dec 2024 14:20:12 EST

MD Anderson and AmMax Bio Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

University of Texas MD Anderson Cancer Center — Tue, 10 Dec 2024 08:00:59 EST

MD Anderson and AmMax Bio announced agreements to develop and advance AmMax's AMB-066 monoclonal antibody therapy for colorectal cancer with minimal residual disease.

ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

University of Texas MD Anderson Cancer Center — Mon, 09 Dec 2024 20:00:38 EST

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH

Roswell Park Comprehensive Cancer Center — Mon, 09 Dec 2024 19:30:00 EST

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.

KU Medical Center Evaluating Smoking-Cessation Interventions for Black Adults in a Five-State Study

University of Kansas Cancer Center — Mon, 09 Dec 2024 14:55:28 EST

The University of Kansas Medical Center is partnering with the University of Wisconsin Center for Tobacco Research and Intervention to determine what treatments work best to help Black people to quit smoking. Their research is funded with a $10 million award from the Patient-Centered Outcomes Research Institute.

Heavy Metal Gut: A $1.9 million Study

University of New Mexico Comprehensive Cancer Center — Mon, 09 Dec 2024 11:30:41 EST

Julie In, PhD, received a $1.9 million grant from the National Institute of Environmental Health Sciences to study the impact of uranium on the cells that line the intestines.

Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows

Roswell Park Comprehensive Cancer Center — Sun, 08 Dec 2024 16:30:07 EST

Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.